CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Beam Therapeutics' BEAM-301 Eliminates Starch Supplementation in Two Patients in Early Trial

By Public Technologies
  • Beam Therapeutics reported initial Phase 1/2 results for BEAM-301 in six patients with glycogen storage disease type Ia on Oct. 27, 2026.
  • Two of three patients receiving 40 mg achieved 15 hours of controlled fasting, eliminating daily starch supplementation at their latest assessments.
  • Median fasting tolerance at Day 36 rose from 2.5 to 15 hours with 40 mg, versus 2.9 to 4.3 hours with 20 mg.
  • Four of six patients experienced serious treatment-related adverse events; no dose-limiting toxicities occurred.
  • Enrollment in the 60 mg cohort is underway; the company plans FDA discussions on a potential approval pathway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270700PRIMZONEFULLFEED9853626) on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.